The mesoaccumbens projection, formed by ventral tegmental area dopamine neu
rons synapsing on nucleus accumbens gamma-aminobutyl ic acid neurons, has b
een implicated in the pathogenesis of schizophrenia and drug addiction. Des
pite intensive study, the nature of the signal conveyed by dopamine neurons
has not been fully resolved. In addition to several slower, dopamine-media
ted, modulatory actions, several lines of evidence suggest that dopamine ne
urons have fast excitatory actions. To rest this, we placed dopamine neuron
s together with accumbens neurons in microcultures. Surprisingly, most dopa
mine neurons made excitatory recurrent connections (autapses), which provid
ed a basis for their identification; accumbens gamma-aminobutyric acid neur
ons were identified by their distinctive size. In 75% of mesoaccumbens cell
pairs, stimulation of the dopamine neuron evoked a glutamate mediated, exc
itatory synaptic response in the accumbens neuron. Immunostaining revealed
dopamine neuron varicosities that were predominantly dopaminergic, ones tha
t were predominantly glutamatergic, and ones that were both dopaminergic an
d glutamatergic. Despite close appositions of both glutamatergic and dopami
nergic varicosities to the dendrites of accumbens neurons, only glutamaterg
ic synaptic responses were seen. In the majority of cell pairs, pharmacolog
ic activation of D2-type dopamine receptors inhibited glutamatergic respons
es, presumably via immunocytochemically-visualized presynaptic D2 receptors
. In some cell pairs, the evoked autaptic and synaptic responses were disco
rdant, suggesting that D2 receptors may be differentially trafficked to dif
ferent presynaptic varicosities.
Thus, dopamine neurons appear to mediate both slow dopaminergic and fast gl
utamatergic actions via separate sets of synapses. Together with evidence f
or glutamate cotransmission in serotonergic raphe neurons and noradrenergic
locus coeruleus neurons, these results add a new dimension to monoamine ne
uron signaling that may have important implications for neuropsychiatric di
sorders. (C) 2000 IBRO. Published by Elsevier Science Ltd. All rights reser
ved.